T2DM合并代谢相关脂肪性肝病患者血清IFN-α和IFN-β水平变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2025.04.020

摘要/Abstract

摘要： 目的分析2型糖尿病(T2DM)合并代谢相关脂肪性肝病(MAFLD)患者血清干扰素(IFN)-α和IFN-β水平变化及其临床意义。方法 2021年9月～2024年8月我院收治的T2DM患者87例和T2DM合并MAFLD患者63例。采用ELISA法检测血清IFN-α和IFN-β水平。应用二元多因素Logistic回归分析T2DM合并MAFLD发生的危险因素,应用受试者工作特征曲线(ROC)分析预测效能。结果 T2DM合并MAFLD组BMI、合并高血压占比、血清TC、TG、LDL-C、UA、IFN-α和IFN-β水平分别为(26.9±2.6)kg/m²、74.6%、(6.8±1.4)mmol/L、(4.3±1.7)mmol/L、(3.7±0.6)μmol/L、(477.1±31.2)μmol/L、(27.9±8.5)pg/mL和(260.1±59.2)pg/mL,均显著高于T2DM组【分别为(24.9±2.2)kg/m²、24.1%、(5.6±1.1)mmol/L、(2.2±0.6)mmol/L、(3.2±0.8)mmol/L、(329.7±30.1)μmol/L、(21.9±4.1)pg/mL和(205.7±51.8)pg/mL,P＜0.05】;采用多因素Logistic回归分析结果显示BMI、血清UA、IFN-α和IFN-β水平均为T2DM合并MAFLD的危险因素(P＜0.05);ROC曲线分析显示,血清IFN-α和IFN=β水平联合预测T2DM合并MAFLD的AUC为0.832,其灵敏度为73.0%,特异度为87.4%,显著优于两指标单独预测(P＜0.05)。结论监测T2DM患者血清IFN-α和IFN-β水平变化可能有助于早期发现MAFLD的存在,指导临床及时进行合适的干预。

Abstract: Objective The aim of this study was to explore clinical implications of serum interferon (IFN)-α and IFN-β levels in patients with type 2 diabetes mellitus (T2DM)and metabolic dysfunction-associated fatty liver disease (MAFLD). Methods 87 patients with T2DM and 63 patients with T2DM and MAFLD were encountered in our hospital between September 2021 and August 2024. Serum IFN-α and IFN-β levels were assayed by ELISA, multivariate Logistic regression analysis was conducted to find risk factors forMAFLD in patients with T2DM, and receiver operating characteristic (ROC) curve was applied to analyze predictive performance. Results BMI, concomitant blood hypertension, serum total cholesterol, total triglyceride, low density lipoprotein-cholesterol, uric acid (UA), IFN-α and IFN-β levels in patients with T2DM and MAFLD were (26.9±2.6)kg/m², 74.6%, (6.8±1.4)mmol/L, (4.3±1.7)mmol/L, (3.7±0.6)μmol/L, (477.1±31.2)μmol/L, (27.9±8.5)pg/mL and (260.1±59.2)pg/mL, all significantly higher than [(24.9±2.2)kg/m², 24.1%, (5.6±1.1)mmol/L, (2.2±0.6)mmol/L, (3.2±0.8)mmol/L, (329.7±30.1)μmol/L, (21.9±4.1)pg/mLand (205.7±51.8)pg/mL, respectively, P＜0.05] in patients with T2DM; multivariate Logistic regression analysis showed that BMI, serum UA, IFN-α and IFN-β levels were all the independent risk factors for patients with T2DM and MAFLD (P＜0.05); ROC analysis demonstrated that the AUC was 0.832, with sensitivity of 73.0% and specificity of 87.4% when serum IFN-α and IFN=β level combination was applied to predict MAFLD in patients with T2DM (P＜0.05). Conclusion Serum IFN-α and IFN-β levelsare significantlyelevated in patients with T2DM and MAFLD, and surveillance of them might help clinicians evaluate the progress of the entity.

Key words: Metabolic dysfunction-associated fatty liver disease, Type 2 diabetes mellitus, Interferon-α, IFN-β, Clinical implications

杨浩, 易波, 刘洪岩. T2DM合并代谢相关脂肪性肝病患者血清IFN-α和IFN-β水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(4): 557-560.

Yang Hao, Yi Bo, Liu Hongyan. Clinical implications of serum IFN-α and IFN-β levels in patients with T2DM and metabolic-associated fatty liver disease[J]. Journal of Practical Hepatology, 2025, 28(4): 557-560.

参考文献

[1] Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology,pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol,2022,28(39):5691-5706.
[2] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD. J Hepatol,2024,81(3):492-542.
[3] Ohno R, Kaneko H, Suzuki Y, et al. Association of metabolic dysfunction-associated fatty liver disease with risk of HF and AF. JACC Asia,2023,3(6):908-921.
[4] Sun DQ, Targher G, Byrne CD, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.Hepatobil Surg Nutr,2023,12(3):386-403.
[5] 朱海伟, 梁琳琅. 2型糖尿病合并非酒精性脂肪性肝病患者维生素D水平与肝纤维化的关系. 中国临床研究,2023,36(5):670-674.
[6] Ghrayeb A, Finney AC, Agranovich B, et al. Serine synthesis via reversed SHMT2 activity drives glycine depletion and acetaminophen hepatotoxicity in MASLD. Cell Metab,2024,36(1):116-129.
[7] Chin EN, Sulpizio A, Lairson LL. Targeting STING to promote antitumor immunity. Trends Cell Biol,2023,33(3):189-203.
[8] Preeti K, Sood A, Fernandes V, et al. Experimental type 2 diabetes and lipotoxicity-associated neuroinflammation involve mitochondrial DNA-mediated cGAS/STING axis: implication of type-1 interferon response in cognitive impairment. Mol Neurobiol,2024,61(9):6217-6244.
[9] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版). 中华糖尿病杂志,2021,13(4):315-409.
[10] 中华医学会肝病学分会.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版). 实用肝脏病杂志,2024,27(4):494-510.
[11] Nanda M, Sharma R, Mubarik S, et al. Type-2 diabetes mellitus (T2DM):Spatial-temporal patterns of incidence,mortality and attributable risk factors from 1990 to 2019 among 21 world regions. Endocrine,2022,77(3):444-454.
[12] Wang K, Liu J. Positive association of the anti-aging protein α-Klotho with insulin resistance and its inverse L-shaped relationship with glycaemic control in the middle-aged and elderly population. Endocrine,2024,86(1):143-155.
[13] Luukkonen PK, Qadri S, Ahlholm N, et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol,2022,76(3):526-535.
[14] Kumar P, Liu C, Suliburk J, et al. Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency,oxidative stress,mitochondrial dysfunction,inflammation,physical function,and aging hallmarks:A randomized clinical trial. J Gerontol A Biol,2023,78(1):75-89.
[15] 王慧, 汤展, 常文娟, 等.非肥胖型与肥胖型非酒精性脂肪性肝病患者代谢特征和肝脂肪变程度比较. 实用肝脏病杂志,2022,25(5):669-672.
[16] Angelini G, Panunzi S, Castagneto-Gissey L, et al. Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis. Gut,2023,72(2):392-403.
[17] Badmus OO, Hillhouse SA, Anderson CD, et al. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD):functional analysis of lipid metabolism pathways. Clin Sci(Lond),2022,136(18):1347-1366.
[18] Clare K, Dillon JF, Brennan PN. Reactive oxygen species and oxidative stress in the pathogenesis of MAFLD. J Clin Transl Hepato,2022,10(5):939-946.
[19] Sawada K, Chung H, Softic S, et al. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease. Cell Metab,2023,35(11):1852-1871.
[20] Wu H, Zhou M, Jin Q, et al. The upregulation of annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver disease. Hepatol Int,2024,18(4):1144-1157.
[21] Ryu S, Sidorov S, Ravussin E, et al. The matricellular protein SPARC induces inflammatory interferon-response in macrophages during aging. Immunity,2022,55(9):1609-1626.
[22] Nishida Y, Yagi H, Ota M, et al. Oxidative stress induces MUC5AC expression through mitochondrial damage-dependent STING signaling in human bronchial epithelial cells. Faseb Bioadv,2023,5(4):171-181.
[23] Sack KD, Eaton N, Tehrani MD, et al. Interferons prime the endothelium for toll-like receptor-mediated thrombin generation. J Thromb Haemost,2024,22(4):1215-1222.
[24] 丁晓洁, 张永明, 宋海燕, 等.2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨.实用肝脏病杂志,2023,26(6):815-818.

T2DM合并代谢相关脂肪性肝病患者血清IFN-α和IFN-β水平变化及其临床意义探讨^*

Clinical implications of serum IFN-α and IFN-β levels in patients with T2DM and metabolic-associated fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张淑玮, 张惠娟, 周杰. 罗格列酮联合二甲双胍治疗非酒精性脂肪性肝病合并T2DM患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 545-548.
[2]	韩煜东, 张杰, 章文瑾, 何年安. 超声来源的脂肪分数诊断代谢相关脂肪性肝病应用研究[J]. 实用肝脏病杂志, 2025, 28(4): 553-556.
[3]	刘倩, 杨洁, 张静, 宫克, 郭瑞丹. 慢性乙型肝炎合并代谢相关脂肪性肝病患者外周血单个核细胞Galectin-3和Galectin-9水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(3): 338-341.
[4]	卫涛涛, 刘天烨, 戴高中. 代谢相关脂肪性肝病患者回肠菌群特征研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 354-357.
[5]	徐玲玲, 卢远, 郑燕钗, 杨本场. 二甲双胍联合双环醇治疗非酒精性脂肪性肝炎患者短期疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 358-361.
[6]	董旭, 王超群, 陈怡, 朱彤, 葛玲玲, 徐爱静. 估算葡萄糖处置率评估无糖尿病人群代谢相关脂肪性肝病发生风险效能研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 362-365.
[7]	秦浩, 方春华, 何競, 张磊, 冉斌, 汪丽萍, 张振华. 六种无创评分诊断2型糖尿病合并代谢相关脂肪性肝病患者效能比较^*[J]. 实用肝脏病杂志, 2025, 28(3): 366-369.
[8]	王新田, 康晓波, 吴霞, 韦颖. 非酒精性脂肪性肝病患者血清OCN、β-CTX和血管紧张素水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(3): 378-381.
[9]	曾艾, 王聪, 李敏, 赵伊婷, 张琴, 何梅. 剪切波弹性成像联合APRI诊断2型糖尿病合并NAFLD患者肝纤维化程度价值研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 382-385.
[10]	熊钻, 程丰, 刘庆, 王亚, 沈利华. 药物性肝损伤患者血清miR-122、IL-1β和IL-10水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(3): 386-389.
[11]	吴彬彬, 李丹丹, 王子铭. 非酒精性脂肪性肝病合并2型糖尿病患者尿微量白蛋白及血清糖化血红蛋白和甲状腺激素水平变化^*[J]. 实用肝脏病杂志, 2025, 28(2): 210-213.
[12]	黄嘉伟, 纪雅丽, 周玲, 陈金军. 代谢相关脂肪性肝病患者SAF评分和脂肪肝进展抑制算法应用研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 48-51.
[13]	伊芬秀, 伊芬锦, 娄仲雷. 2型糖尿病合并细菌性肝脓肿患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 935-938.
[14]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[15]	李艳敏, 张维, 胡彦彦, 齐蕾. 老年非酒精性脂肪性肝病合并2型糖尿病患者血清TyG、内脏/皮下脂肪面积比和心脏代谢指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(5): 697-700.